12 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Werewolf Therapeutics, Inc. portfolio ends in May 2039, and more of its terms end in 2039 (10) than in any other year. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2039
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2039 · Low confidence
Also notable
Ends May 2039 · High confidence
Also notable
Ends no later than May 2040 · Medium confidence
Also notable
Ends May 2039 · Low confidence
Activatable Interleukin 12 Polypeptides and Methods of Use Thereof
US 11,453,710
Cited by 16 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Activatable INTERLEUKIN-2 Polypeptides
US 10,696,724
Cited by 15 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2039.
Separation Moieties and Methods of Use Thereof
US 11,739,132
Granted 2023. Computed term ends 2040. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Activatable Cytokine Polypeptides and Methods of Use Thereof
US 12,617,829
A family of 5 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 28, 2027The maintenance fee for Separation Moieties and Methods of Use Thereof (US 11,739,132) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof (US 11,981,716) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
- Oct 15Assignment recorded on 25 records: Werewolf Therapeutics, Inc. to EMD Serono Research & Development Institute, Inc. Recorded Oct 15, 2026, executed Aug 14, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76677, frame 66.
- Oct 13Assignment recorded on 1 record: Werewolf Therapeutics, Inc. to EMD Serono Research & Development Institute, Inc. Recorded Oct 13, 2026, executed Aug 14, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76687, frame 1.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Activatable INTERLEUKIN-2 Polypeptides | 5 in force | to Jul 2039 |
| Activatable Interleukin 12 Polypeptides | 3 in force | to May 2039 |
| Activatable Cytokine Polypeptides and Methods of Use Thereof (2022) | 2 in force | to Nov 2040 |
| Separation Moieties and Methods of Use Thereof | 1 in force | to May 2040 |
| Activatable Cytokine Polypeptides and Methods of Use Thereof (2024) | 1 in force | to May 2039 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,696,723 | Activatable Interleukin 12 Polypeptides held by EMD Serono, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 10,696,724 | Activatable INTERLEUKIN-2 Polypeptides held by EMD Serono, Inc. In force · High confidence | In force | High confidence | |
| US 11,352,403 | Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof held by EMD Serono, Inc. In force · High confidence | In force | High confidence | |
| US 11,453,710 | Activatable Interleukin 12 Polypeptides and Methods of Use Thereof held by EMD Serono, Inc. In force · Low confidence | In force | Low confidence | |
| US 11,535,658 | Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof held by EMD Serono, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,036,266 | Activatable Cytokine Polypeptides and Methods of Use Thereof held by EMD Serono, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,275,769 | Activatable Interleukin 12 Polypeptides and Methods of Use Thereof held by EMD Serono, Inc. In force · Low confidence | In force | Low confidence | |
| US 12,534,505 | Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof held by EMD Serono, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,617,829 | Activatable Cytokine Polypeptides and Methods of Use Thereof held by EMD Serono, Inc. In force · Low confidence | In force | Low confidence | |
| US 11,981,716 | Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof held by EMD Serono, Inc. In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 12: 14 applications pending · 3 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.